This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Gastroduodenal Erosions
and you are
between 18 and 55
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

Oxford Pharmascience Ltd (the Sponsor) is developing a new naproxen tablet formulation (the study drug, OXP005), for the potential treatment of rheumatic and painful conditions. The study will compare the study drug to an already marketed formulation of prescription strength naproxen (Naprosyn® the reference product) by looking at the relative impact of both products on gastroduodenal (GD) irritation by performing a specialist procedure called an endoscopy (or more specifically, a gastroscopy). The safety and tolerability of the study drug will also be assessed.

Provided treatments

  • Drug: OXP005
  • Drug: Naproxen
Tris trial is registered with FDA with number: NCT02408978. The sponsor of the trial is Oxford Pharmascience Ltd and it is looking for 0 volunteers for the current phase.
Official trial title: